Cullinan Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
13/05/2025 13:00
Cullinan Therapeutics Inc CGEM.OQ reported a quarterly adjusted loss of 74 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -86 cents. The mean expectation of nine analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from -86 cents to -74 cents per share. Reported revenue was zero; analysts expected zero. Cullinan Therapeutics Inc's reported EPS for the quarter was a loss of 74 cents. The company reported a quarterly loss of $48.5 million. Cullinan Therapeutics Inc shares had risen by 4.5% this quarter and lost 35.1% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 1.2% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Cullinan Therapeutics Inc is $32.00 This summary was machine generated from LSEG data May 13 at 12:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.80 | -0.74 | Beat |
| Dec. 31 2024 | -0.76 | -0.73 | Beat |
| Sep. 30 2024 | -0.81 | -0.69 | Beat |
| Jun. 30 2024 | -0.73 | -0.75 | Missed |